Aldeyra Therapeutics Inc (STU:137)
€ 4.654 -0.037 (-0.79%) Market Cap: 276.29 Mil Enterprise Value: 184.32 Mil PE Ratio: 0 PB Ratio: 3.43 GF Score: 39/100

Aldeyra Therapeutics Inc Conference Call and Webcast Transcript

Dec 20, 2021 / 10:00PM GMT
Release Date Price: €6.35 (+1.60%)
Operator

Good afternoon, and welcome to the Aldeyra Therapeutics Conference Call. (Operator Instructions) I would now like to hand the conference over to Joshua Reed, Chief Financial Officer. Thank you. Sir, please go ahead.

Joshua Reed
Aldeyra Therapeutics, Inc. - CFO

Thank you, and good afternoon, everyone. On the call with me is Dr. Todd Brady, Aldeyra's President and Chief Executive Officer. Please turn to Slide 2. This presentation and various remarks, which may be made during this presentation contain forward-looking statements regarding Aldeyra and its investigational drug candidate, reproxalap.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aldeyra's actual results, performance or achievement to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

These statements reflect Aldeyra's current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot